Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2007 1
2009 2
2010 1
2011 3
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 3
2019 1
2020 1
2021 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Targeted therapy: a new hope for thyroid carcinomas.
Perri F, Pezzullo L, Chiofalo MG, Lastoria S, Di Gennaro F, Scarpati GD, Caponigro F. Perri F, et al. Crit Rev Oncol Hematol. 2015 Apr;94(1):55-63. doi: 10.1016/j.critrevonc.2014.10.012. Epub 2014 Nov 1. Crit Rev Oncol Hematol. 2015. PMID: 25465739 Review.
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.
Trotta AM, Aurilio M, D'Alterio C, Ieranò C, Di Martino D, Barbieri A, Luciano A, Gaballo P, Santagata S, Portella L, Tomassi S, Marinelli L, Sementa D, Novellino E, Lastoria S, Scala S, Schottelius M, Di Maro S. Trotta AM, et al. J Med Chem. 2021 Mar 25;64(6):3449-3461. doi: 10.1021/acs.jmedchem.1c00066. Epub 2021 Mar 4. J Med Chem. 2021. PMID: 33660512
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, Tomassi S, Messere A, Sementa D, Lastoria S, Carotenuto A, Novellino E, Scala S, Marinelli L. Di Maro S, et al. J Med Chem. 2017 Dec 14;60(23):9641-9652. doi: 10.1021/acs.jmedchem.7b01062. Epub 2017 Nov 20. J Med Chem. 2017. PMID: 29125295
Pulmonary Cladophialophora boppii infection in a lung transplant recipient: case report and literature review.
Lastoria C, Cascina A, Bini F, Di Matteo A, Cavanna C, Farina C, Carretto E, Meloni F. Lastoria C, et al. J Heart Lung Transplant. 2009 Jun;28(6):635-7. doi: 10.1016/j.healun.2009.02.014. Epub 2009 May 5. J Heart Lung Transplant. 2009. PMID: 19481026 Review.
Cladophialophora boppii is a dematiaceous fungus, which has been reported only rarely to be the cause of cutaneous infection. Herein we describe a C boppii parenchymal and bronchial infection in a lung transplant recipient. ...
Cladophialophora boppii is a dematiaceous fungus, which has been reported only rarely to be the cause of cutaneous infection. Herein we desc …
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.
Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco' C, Di Gennaro F, Capobianco G, Giovannoni L, Menssen HD, Neri D, Pinto A, Lastoria S. Aloj L, et al. Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435772 Clinical Trial.
PURPOSE: The extra-domain A1 of tenascin-C (TC-A1) is highly expressed in the extracellular matrix of tumours and on newly formed blood vessels and is thus a valuable target for radionuclide therapy. ...
PURPOSE: The extra-domain A1 of tenascin-C (TC-A1) is highly expressed in the extracellular matrix of tumours and on newly formed blo …
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice.
Pirozzi Palmese V, D'Ambrosio L, Di Gennaro F, Maisto C, de Marino R, Morisco A, Coluccia S, Di Gennaro P, De Lauro F, Raddi M, Gaballo P, Tafuto S, Celentano E, Lastoria S. Pirozzi Palmese V, et al. Eur J Nucl Med Mol Imaging. 2023 May;50(6):1753-1764. doi: 10.1007/s00259-023-06112-8. Epub 2023 Jan 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36688980 Free PMC article.
Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies.
Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Sangro B, et al. Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1721-1730. doi: 10.1007/s00259-018-3968-5. Epub 2018 Mar 7. Eur J Nucl Med Mol Imaging. 2018. PMID: 29516130 Free PMC article.
Median (95% confidence interval [CI]) survival following radioembolisation was similar between procedure-naive and prior treatment groups for Barcelona Clinic Liver Cancer (BCLC) stage A: 22.1 months (15.1-45.9) versus 30.9 months (19.6-46.8); p = 0.243); stage B: 18.4 months (11 …
Median (95% confidence interval [CI]) survival following radioembolisation was similar between procedure-naive and prior treatment groups fo …
On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact.
Maisto C, Morisco A, de Marino R, Squame E, Porfidia V, D'Ambrosio L, Di Martino D, Gaballo P, Aurilio M, Buonanno M, Esposito A, Raddi M, Lastoria S. Maisto C, et al. EJNMMI Radiopharm Chem. 2021 Oct 13;6(1):36. doi: 10.1186/s41181-021-00150-z. EJNMMI Radiopharm Chem. 2021. PMID: 34643830 Free PMC article.
In this study, PSMA-1007 has been labeled with low (A), medium (B) and high (C) starting activities of [(18)F]fluoride, in order to verify if radiochemical yield, radiochemical purity and stability of [(18)F]PSMA-1007 were affected. ...Furthermore, radiochemical stability …
In this study, PSMA-1007 has been labeled with low (A), medium (B) and high (C) starting activities of [(18)F]fluoride, in order to v …
Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
Morabito A, Manzo A, Montanino A, Rachiglio AM, Sforza V, Pasquale R, Costanzo R, Maiello MR, Sandomenico C, Gallo M, Palumbo G, De Luca A, La Rocca A, Martucci N, De Cecio R, Picone C, Lastoria S, Normanno N. Morabito A, et al. Oncologist. 2022 Feb 3;27(1):7-12. doi: 10.1093/oncolo/oyab002. Oncologist. 2022. PMID: 35305107 Free PMC article.
The MTB suggested NGS testing of tumor biopsy that revealed a rare exon-20 EGFR insertion (p.His773dup; c.2315_2316insCCA) and EGFR amplification. The MTB recommended treatment with erlotinib and follow-up with liquid biopsy, by using both cell-free DNA (cfDNA) and circula …
The MTB suggested NGS testing of tumor biopsy that revealed a rare exon-20 EGFR insertion (p.His773dup; c.2315_2316insCCA) and EGFR a …
26 results